Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

This study is testing low-dose nivolumab (an immunotherapy drug) in adults living with HIV who are on stable antiretroviral therapy (ART). The goal is to see if this drug can reduce the "HIV reservoir" — the hidden pool of HIV that persists even when viral load is undetectable. **You may be eligible if...** - You have HIV-1 infection and have been on the same antiretroviral treatment for at least 4 weeks - Your HIV viral load has been undetectable (below 50 copies/mL) for at least 2 years - Your CD4+ cell count is above 500 cells/μL - You weigh at least 50 kg - You are willing to use effective contraception if of reproductive potential **You may NOT be eligible if...** - You have an active autoimmune disease - You have a history of organ transplant or chronic lung disease (COPD) - You have type 1 diabetes - You have had an HIV-related opportunistic infection within the past 2 years - You have previously received an immune checkpoint inhibitor - You are pregnant or breastfeeding - You have active tuberculosis or active hepatitis B Talk to your doctor to see if this trial is right for you.